BioCorRx Inc. (BICX) Form 10-Q — Nov 16, 2026
BioCorRx filed its Q3 2026 10-Q with an explicit going-concern warning: cash was just $18,233 against a working capital deficit of $8,652,785, and management says substantial…
Key figures
- Total Debt
- $1,254,384 notes payable plus $847,763 related-party notes; working capital deficit of $8,652,785
- Revenue Yoy
- -81.7% (three months: -40,348 vs 213,910)
- Cash Position
- 18233
- Shares Outstanding
- 30524083
- Shares issued yoy
- 30,524,083 vs 24,489,311 at Dec 31, 2025 (~25% increase)
- Rd expense nine months
- 1810781
- Grant income nine months
- 1810748
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.